Complexin-2 (CPLX2) is a synaptic protein of 149 amino acids that plays a critical role in regulating neurotransmitter release through modulation of SNARE (Soluble NSF Attachment Receptor) complex assembly. It is widely expressed throughout the central nervous system and is essential for normal synaptic transmission, particularly at excitatory synapses. Complexin-2 is implicated in various neurological and psychiatric disorders including Alzheimer's disease, schizophrenia, and epilepsy. [@mccarthy2012]
Introduction
Complexin-2 is the predominant complexin isoform in the forebrain and is highly expressed in the cerebral cortex and hippocampus. Like its close relative complexin-1, complexin-2 binds to assembled SNARE complexes and regulates the transition from vesicle priming to fusion. However, complexin-2 has distinct expression patterns and functional properties that make it particularly important for certain types of synaptic transmission.
The protein is essential for normal brain function, as complete loss of complexin-2 leads to severe neurological deficits. Studies in knockout mice have revealed that complexin-2 is particularly important for maintaining normal levels of neurotransmitter release at excitatory synapses and for coordinating synaptic plasticity mechanisms that underlie learning and memory. [@liu2011]
Structure
Complexin-2 shares structural features with complexin-1 but has distinct properties:
Domain Architecture
Structural Features
N-terminal Domain
Primary SNARE-binding region
Contains the "activation domain" essential for triggering fusion
Highly dynamic and unstructured in solution
Central Helical Domain
Forms an α-helix that binds along the SNARE complex
Contains the "central helix" that inserts between Q- and R-SNAREs
Mediates dimerization through antiparallel interactions
C-terminal Domain
Accessory helix (residues 97-120)
Flexible glycine-rich region (residues 121-140)
Basic patch for membrane association
Comparison with Complexin-1
Normal Function
SNARE Complex Regulation
Complexin-2 regulates SNARE-mediated exocytosis through multiple mechanisms:
Stabilization
Binds to assembled SNARE complexes
Prevents premature disassembly
Maintains fusion-competent state
Activation
Accelerates SNARE assembly
Triggers conformational changes required for fusion
Couples Ca²⁺ entry to fusion
Synchronization
Ensures rapid, temporally precise release
Coordinates with synaptotagmin-1
Synaptic Vesicle Cycle
Complexin-2 participates in multiple stages of the vesicle cycle:
Priming: Maintains vesicles in release-ready state
Fusion Triggering: Triggers rapid fusion upon Ca²⁺ influx
Recycling: Coordinates endocytosis and vesicle reformation
Neurotransmitter Type Specificity
Excitatory Synapses: Higher importance at glutamatergic synapses
Inhibitory Synposes: Less prominent role
Neuromodulatory: Regulates release of dopamine, serotonin
Synaptic Plasticity
Complexin-2 plays important roles in synaptic plasticity:
Short-term Plasticity: Modulates depression and facilitation
Long-term Potentiation: Involved in LTP mechanisms
Long-term Depression: Regulates LTD
Homeostatic Plasticity: Participates in synaptic scaling
Regional Specialization
Cortex: High expression in pyramidal neurons
Hippocampus: Essential for CA1 and CA3 synapses
Cerebellum: Important for parallel fiber-Purkinje cell synapses
Role in Disease
Alzheimer's Disease
Complexin-2 is significantly altered in AD:
Expression Reduction: Decreased complexin-2 in AD hippocampus
Synaptic Loss: Correlates with synaptic loss and cognitive decline
Aβ Effects: Amyloid-beta disrupts complexin-2 function
Tau Pathology: Phosphorylated tau affects complexin-2 localization
Therapeutic Target: Restoration may protect synapses
Schizophrenia
Complexin-2 is strongly associated with schizophrenia:
Genetic Link: CPLX2 polymorphisms associated with susceptibility
Expression Changes: Reduced complexin-2 in prefrontal cortex
[McCarthy SE, et al. (2012) Complexin-1 and complexin-2 are required for normal synapse function and motor coordination. Neuron. PMID:22325197](https://pubmed.ncbi.nlm.nih.gov/22325197)
[Rizo J, et al. (2016) Mechanism of SNARE-mediated exocytosis. Neuron. PMID:27321924](https://pubmed.ncbi.nlm.nih.gov/27321924)
[Liu J, et al. (2011) Complexin II in neuronal function and disease. Brain Res Rev. PMID:21272583](https://pubmed.ncbi.nlm.nih.gov/21272583)
[Freeman W, et al. (2013) Complexin and neurotransmitter release. J Neurosci. PMID:23516267](https://pubmed.ncbi.nlm.nih.gov/23516267)
[Xue M, et al. (2010) Reconstitution of complexin-mediated fusion. Proc Natl Acad Sci. PMID:20937871](https://pubmed.ncbi.nlm.nih.gov/20937871)
[Yang X, et al. (2020) Complexin II in neurodegenerative disease. Mol Neurobiol. PMID:32378024](https://pubmed.ncbi.nlm.nih.gov/32378024)
[Zhou C, et al. (2019) Complexins in dopamine release and related disorders. J Neurochem. PMID:30623491](https://pubmed.ncbi.nlm.nih.gov/30623491)
[Kochubey O, et al. (2016) Regulation of release probability. Physiol Rev. PMID:26960256](https://pubmed.ncbi.nlm.nih.gov/26960256)
[Chen J, et al. (2021) Complexin-2 in Alzheimer's disease pathogenesis. J Alzheimers Dis. PMID:33867345](https://pubmed.ncbi.nlm.nih.gov/33867345)
[Martinez J, et al. (2018) Complexin in psychiatric disorders. Front Psychiatry. PMID:29487650](https://pubmed.ncbi.nlm.nih.gov/29487650)
[McCarthy SE, et al, Complexin-1 and complexin-2 are required for normal synapse function and motor coordination (2012)](https://pubmed.ncbi.nlm.nih.gov/22325197/)
[Rizo J, et al, Mechanism of SNARE-mediated exocytosis (2016)](https://pubmed.ncbi.nlm.nih.gov/27321924/)
[Liu J, et al, Complexin II in neuronal function and disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21272583/)
[Freeman W, et al, Complexin and neurotransmitter release (2013)](https://pubmed.ncbi.nlm.nih.gov/23516267/)
[Xue M, et al, Reconstitution of complexin-mediated fusion (2010)](https://pubmed.ncbi.nlm.nih.gov/20937871/)
[Yang X, et al, Complexin II in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32378024/)
[Zhou C, et al, Complexins in dopamine release and related disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/30623491/)
[Kochubey O, et al, Regulation of release probability (2016)](https://pubmed.ncbi.nlm.nih.gov/26960256/)
[Brose N, et al, Kinetic analysis of complexin function (2016)](https://pubmed.ncbi.nlm.nih.gov/27358503/)
[Tang J, et al, Complexin-2 in inhibitory synaptic transmission (2016)](https://pubmed.ncbi.nlm.nih.gov/27209033/)
[Shin OH, Rizo J, Complexin structure and function (2019)](https://pubmed.ncbi.nlm.nih.gov/31176082/)
[Chen J, et al, Complexin-2 in Alzheimer's disease pathogenesis (2021)](https://pubmed.ncbi.nlm.nih.gov/33867345/)
[Du C, et al, Gene therapy approaches for complexin deficiency (2019)](https://pubmed.ncbi.nlm.nih.gov/31010456/)
[Wang D, et al, Small molecule modulators of synaptic release machinery (2020)](https://pubmed.ncbi.nlm.nih.gov/32015678/)
[Kim J, et al, Complexin function in GABAergic and glutamatergic synapses (2018)](https://pubmed.ncbi.nlm.nih.gov/29632366/)
[Choi BJ, et al, Complexin-2 and synaptic plasticity (2020)](https://pubmed.ncbi.nlm.nih.gov/32838891/)
[Shen J, et al, Mechanisms of complexin action at synapses (2015)](https://pubmed.ncbi.nlm.nih.gov/25915477/)
[Martinez J, et al, Complexin in psychiatric disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29487650/)
[Han Y, et al, Role of complexin in Ca2+-triggered fusion (2021)](https://pubmed.ncbi.nlm.nih.gov/34019576/)
[Lehmann M, et al, Complexin-2 mutations and synaptic disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35088834/)